Repligen (NASDAQ:RGEN – Get Free Report) and VivoSim Labs (NASDAQ:VIVS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Profitability
This table compares Repligen and VivoSim Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | -1.47% | 5.49% | 3.93% |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Repligen and VivoSim Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 1 | 3 | 12 | 2 | 2.83 |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
Repligen currently has a consensus target price of $178.57, indicating a potential upside of 6.46%. Given Repligen’s stronger consensus rating and higher probable upside, analysts clearly believe Repligen is more favorable than VivoSim Labs.
Risk & Volatility
Repligen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
Institutional and Insider Ownership
97.6% of Repligen shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 1.0% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Repligen and VivoSim Labs”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $805.61 million | 13.31 | $48.89 million | ($0.21) | -798.73 |
| VivoSim Labs | $130,000.00 | 17.36 | -$13.84 million | ($4.47) | -0.03 |
Repligen has higher revenue and earnings than VivoSim Labs. Repligen is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Repligen beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.
About Repligen
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
